Conexeu Sciences Inc (CNXU)

$4.45 -0.55 (-11.00%)
Market Cap 133.79M
Revenue (ttm) 0.00
Net Income (ttm) -3.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 124,800
Avg Vol 204,126
Day's Range N/A - N/A
Shares Out 26.76M
Stochastic %K 14%
Beta N/A
Analysts Sell
Price Target $20.00

Company Profile

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting ther...

Industry: Biotechnology
Sector: Healthcare
Phone: (604) 315-4722
Address:
50 West Liberty Street, Suite 880, Reno, United States
thenewmoney
thenewmoney Sep. 16 at 3:03 AM
The Success Of GLP-1s Could Cause A Boom In Medical Aesthetics Next $CNXU https://www.thenew.money/article/the-success-of-glp-1s-could-cause-a-boom-in-medical-aesthetics-next
0 · Reply
PenkeInvesting
PenkeInvesting Sep. 15 at 9:27 AM
I looked at the business behind $CNXU (Conexeu Sciences Inc.) for you. Based on financial data and reported results. #CNXU
0 · Reply
Biotech103
Biotech103 Sep. 11 at 9:59 PM
$CNXU this is the story here. They have no FDA and when they do get an FDA it will be a 510 K for a topical type of indication. They are talking about an indication for GLP face, which is a much longer PMA that will cost millions and millions of dollars and could take 5 to 10 years. That’s where I think the advertising here is shady. In the meantime, they have no revenue. They will need to burn millions and millions of dollars and the only thing they have to fund all of this is stock. This is going to $.10 very quickly.
0 · Reply
hen
hen Sep. 9 at 10:03 PM
$CNXU scam alert
1 · Reply
hen
hen Sep. 9 at 10:02 PM
$CNXU they’re advertising their stock in a newspaper. Never a good sign
0 · Reply
Biotech103
Biotech103 Sep. 6 at 9:59 AM
$CNXU for them to treat facial atrophy for glp volume loss they will need an fda PMA. That’s 5 years from now and about 30-40M depending. The 510K will give them topical or internal off label no reimbursement. No one will Inject cosmetic off label with the 20 on label products available. All this PR is misleading.
0 · Reply
alano2311
alano2311 Sep. 5 at 5:37 PM
$CNXU markets sending a message that they are unafraid of pressuring the atock/company to extreme levels…maybe they think the company needs to do a raise asap(false)…maybe the company will fail fda submission for bovine collagen(unlikely)…this is the hedge for glp-1 which is in the first inning…this is a compelling level and i am patiently buying but regularly on weakness…💪🙏
0 · Reply
Girlheartstox
Girlheartstox Sep. 3 at 7:30 PM
$CNXU I’m a licensed esthetician with 23 years experience in the beauty industry. Ozempic face is a real thing and collagen injectables is a woman’s dream. I’m all for this and have started a position and am willing to be patient. I hope this company is able to solve a real issue, I love the idea of it for skin renewal in general for scar wound care, contouring skin tissue etc!
1 · Reply
BioResearcher
BioResearcher Sep. 1 at 9:09 PM
$CNXU Going to $3 ???? lol
1 · Reply
ZRadly
ZRadly Aug. 23 at 12:41 AM
$CNXU Keep an eye on it😉
0 · Reply
Latest News on CNXU
Conexeu Sciences Quarterly report: Q3 2026

Sep 14, 2026, 7:00 AM EDT - 2 days ago

Conexeu Sciences Quarterly report: Q3 2026

Conexeu Sciences Sets September and October 2026 Conference Schedule

Sep 1, 2026, 8:30 AM EDT - 14 days ago

Conexeu Sciences Sets September and October 2026 Conference Schedule

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Aug 18, 2026, 8:30 AM EDT - 4 weeks ago

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Jul 14, 2026, 8:30 AM EDT - 2 months ago

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Jul 7, 2026, 9:00 AM EDT - 2 months ago

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Jun 25, 2026, 8:30 AM EDT - 2 months ago

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Conexeu Sciences initiated with a Buy at H.C. Wainwright

2026-06-22T10:05:06.000Z - 2 months ago

Conexeu Sciences initiated with a Buy at H.C. Wainwright

Conexeu Sciences appoints David Bogart as chief commercial officer

2026-06-15T13:11:02.000Z - 3 months ago

Conexeu Sciences appoints David Bogart as chief commercial officer

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Jun 15, 2026, 8:30 AM EDT - 3 months ago

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences Quarterly report: Q2 2026

Jun 15, 2026, 8:00 AM EDT - 3 months ago

Conexeu Sciences Quarterly report: Q2 2026

Conexeu Sciences provides update on manufacturing scale up for wound care device

2026-06-08T13:01:13.000Z - 3 months ago

Conexeu Sciences provides update on manufacturing scale up for wound care device

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Jun 8, 2026, 8:30 AM EDT - 3 months ago

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

Jun 3, 2026, 8:30 AM EDT - 3 months ago

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

May 27, 2026, 10:36 AM EDT - 3 months ago

UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

May 27, 2026, 8:30 AM EDT - 3 months ago

Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"

May 21, 2026, 12:02 PM EDT - 3 months ago

Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"

Conexeu Sciences opens at $13.50 after Nasdaq direct listing

2026-05-21T15:45:30.000Z - 3 months ago

Conexeu Sciences opens at $13.50 after Nasdaq direct listing

thenewmoney
thenewmoney Sep. 16 at 3:03 AM
The Success Of GLP-1s Could Cause A Boom In Medical Aesthetics Next $CNXU https://www.thenew.money/article/the-success-of-glp-1s-could-cause-a-boom-in-medical-aesthetics-next
0 · Reply
PenkeInvesting
PenkeInvesting Sep. 15 at 9:27 AM
I looked at the business behind $CNXU (Conexeu Sciences Inc.) for you. Based on financial data and reported results. #CNXU
0 · Reply
Biotech103
Biotech103 Sep. 11 at 9:59 PM
$CNXU this is the story here. They have no FDA and when they do get an FDA it will be a 510 K for a topical type of indication. They are talking about an indication for GLP face, which is a much longer PMA that will cost millions and millions of dollars and could take 5 to 10 years. That’s where I think the advertising here is shady. In the meantime, they have no revenue. They will need to burn millions and millions of dollars and the only thing they have to fund all of this is stock. This is going to $.10 very quickly.
0 · Reply
hen
hen Sep. 9 at 10:03 PM
$CNXU scam alert
1 · Reply
hen
hen Sep. 9 at 10:02 PM
$CNXU they’re advertising their stock in a newspaper. Never a good sign
0 · Reply
Biotech103
Biotech103 Sep. 6 at 9:59 AM
$CNXU for them to treat facial atrophy for glp volume loss they will need an fda PMA. That’s 5 years from now and about 30-40M depending. The 510K will give them topical or internal off label no reimbursement. No one will Inject cosmetic off label with the 20 on label products available. All this PR is misleading.
0 · Reply
alano2311
alano2311 Sep. 5 at 5:37 PM
$CNXU markets sending a message that they are unafraid of pressuring the atock/company to extreme levels…maybe they think the company needs to do a raise asap(false)…maybe the company will fail fda submission for bovine collagen(unlikely)…this is the hedge for glp-1 which is in the first inning…this is a compelling level and i am patiently buying but regularly on weakness…💪🙏
0 · Reply
Girlheartstox
Girlheartstox Sep. 3 at 7:30 PM
$CNXU I’m a licensed esthetician with 23 years experience in the beauty industry. Ozempic face is a real thing and collagen injectables is a woman’s dream. I’m all for this and have started a position and am willing to be patient. I hope this company is able to solve a real issue, I love the idea of it for skin renewal in general for scar wound care, contouring skin tissue etc!
1 · Reply
BioResearcher
BioResearcher Sep. 1 at 9:09 PM
$CNXU Going to $3 ???? lol
1 · Reply
ZRadly
ZRadly Aug. 23 at 12:41 AM
$CNXU Keep an eye on it😉
0 · Reply
Salvadors_poppy
Salvadors_poppy Aug. 19 at 2:59 PM
$CNXU ….
0 · Reply
BioResearcher
BioResearcher Aug. 19 at 2:19 PM
$CNXU This stock is trading like a pump and dump ! lol
0 · Reply
BioResearcher
BioResearcher Aug. 19 at 1:24 PM
$CNXU This is a good article study about the booming market for medical aesthetics injectable market due to weight loss. (CNXU is entering this market with the recent success of their trial to restore large volume of tissue)
0 · Reply
BioResearcher
BioResearcher Aug. 19 at 1:18 PM
$CNXU CNXU is targeting $ BILLIONS dollars market: "..rapid fat loss and muscle loss. This leads to facial volume loss, sagging skin, and an aged look called "Ozempic face." As a result, the aesthetic injectables market is booming..."
0 · Reply
dmplaw1
dmplaw1 Aug. 18 at 10:59 PM
$CNXU I need to obtain more shares.
0 · Reply
BioResearcher
BioResearcher Aug. 18 at 9:43 PM
$CNXU Awesome technology:
1 · Reply
BioResearcher
BioResearcher Aug. 18 at 7:50 PM
$CNXU This company will be worth multi BILLIONs dollars ! Their technology is every woman's dream: the fountain of youth ! "Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body tissue restoration, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review."
0 · Reply
topstockalerts
topstockalerts Aug. 17 at 1:56 PM
$CNXU double digits next
0 · Reply
STACKD0E
STACKD0E Aug. 17 at 1:41 PM
$UPLD $UCL $UFI $CNXU 👁️
0 · Reply
ClassiTrader
ClassiTrader Aug. 14 at 8:17 PM
$CNXU 👀
0 · Reply
Mikiminingmouse
Mikiminingmouse Aug. 13 at 8:02 AM
12 month study complete for $CNXU’s CXU platform! a great milestone checked off management execution stays super steady
0 · Reply
Mikiminingmouse
Mikiminingmouse Aug. 11 at 8:49 AM
$CNXU consolidating nicely in the $7 to $8 range. From technical analysis perspective, solid upside potential for this bio platform as clinical data matures.
0 · Reply